138 related articles for article (PubMed ID: 26373715)
1. Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells.
Wu X; Xiao H; Wang R; Liu L; Li C; Lin J
Curr Cancer Drug Targets; 2016; 16(7):631-8. PubMed ID: 26373715
[TBL] [Abstract][Full Text] [Related]
2. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
4. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
5. Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity.
Wu J; Guo W; Lin SZ; Wang ZJ; Kan JT; Chen SY; Zhu YZ
Cell Death Dis; 2016 Aug; 7(8):e2339. PubMed ID: 27537522
[TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
7. A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.
Xiao H; Bid HK; Jou D; Wu X; Yu W; Li C; Houghton PJ; Lin J
J Biol Chem; 2015 Feb; 290(6):3418-29. PubMed ID: 25313399
[TBL] [Abstract][Full Text] [Related]
8. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Yu PY; Gardner HL; Roberts R; Cam H; Hariharan S; Ren L; LeBlanc AK; Xiao H; Lin J; Guttridge DC; Mo X; Bennett CE; Coss CC; Ling Y; Phelps MA; Houghton P; London CA
PLoS One; 2017; 12(7):e0181885. PubMed ID: 28750090
[TBL] [Abstract][Full Text] [Related]
9. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
[TBL] [Abstract][Full Text] [Related]
10. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
Yao X; Zhu F; Zhao Z; Liu C; Luo L; Yin Z
J Cell Biochem; 2011 Oct; 112(10):2837-49. PubMed ID: 21608020
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract][Full Text] [Related]
12. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.
Wei J; Ma L; Lai YH; Zhang R; Li H; Li C; Lin J
J Exp Clin Cancer Res; 2019 Feb; 38(1):63. PubMed ID: 30736824
[TBL] [Abstract][Full Text] [Related]
13. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
14. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.
Shi Y; Zhou W; Cheng L; Chen C; Huang Z; Fang X; Wu Q; He Z; Xu S; Lathia JD; Ping Y; Rich JN; Bian XW; Bao S
Cell Death Differ; 2017 Jan; 24(1):167-180. PubMed ID: 27740621
[TBL] [Abstract][Full Text] [Related]
15. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer.
Jin J; Guo Q; Xie J; Jin D; Zhu Y
Pathol Oncol Res; 2019 Apr; 25(2):769-775. PubMed ID: 30706361
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
Gariboldi MB; Ravizza R; Molteni R; Osella D; Gabano E; Monti E
Cancer Lett; 2007 Dec; 258(2):181-8. PubMed ID: 17920763
[TBL] [Abstract][Full Text] [Related]
17. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
Wei CC; Ball S; Lin L; Liu A; Fuchs JR; Li PK; Li C; Lin J
Int J Oncol; 2011 Jan; 38(1):279-85. PubMed ID: 21109950
[TBL] [Abstract][Full Text] [Related]
18. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.
Kim MJ; Nam HJ; Kim HP; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Cancer Lett; 2013 Jul; 335(1):145-52. PubMed ID: 23402820
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
Xu S; Grande F; Garofalo A; Neamati N
Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726
[TBL] [Abstract][Full Text] [Related]
20. Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells.
Liu A; Liu Y; Xu Z; Yu W; Wang H; Li C; Lin J
Cancer Sci; 2011 Jul; 102(7):1381-7. PubMed ID: 21435102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
